Adocia SA, a clinical-stage biotechnology company headquartered in Lyon, France, has been making significant strides in the health care sector, particularly within the biotechnology industry. As of October 14, 2025, the company’s stock is trading at 10.8 EUR on the NYSE Euronext Paris, reflecting a notable recovery from its 52-week low of 2.86 EUR on April 6, 2025. With a market capitalization of approximately 197.62 million EUR, Adocia’s financial trajectory underscores its potential and resilience in a competitive market.

At the core of Adocia’s innovative approach is its proprietary BioChaperone technological platform. This platform is a testament to the company’s commitment to enhancing the efficacy and safety of therapeutic proteins through the use of novel polymers, oligomers, and small molecules. The BioChaperone technology is not merely a scientific endeavor but a strategic pivot towards addressing the pressing needs of patients with diabetes and other metabolic diseases.

Adocia’s clinical product pipeline is both diverse and ambitious, featuring a range of insulin formulations designed to cater to various patient needs. Among these are the BioChaperone Lispro U100 and U200, ultra-rapid formulations of insulin analogs that promise quicker onset of action. The HinsBet U100, a rapid-acting formulation of human insulin, and the BioChaperone Combo, which combines basal insulin glargine with rapid-acting insulin lispro, further illustrate the company’s dedication to innovation. Additionally, the BioChaperone Pramlintide Insulin and BioChaperone Human Glucagon represent significant advancements in prandial insulin therapy and glucagon formulation, respectively.

Beyond insulin, Adocia is exploring the therapeutic potential of GLP-1 and GLP-2 analogs. The development of BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide, which combine insulin glargine with GLP-1, alongside BioChaperone Teduglutide for the treatment of short bowel syndrome, and BioChaperone Glucagon GLP-1 for obesity, underscores the company’s broad vision for metabolic disease treatment.

A strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. further amplifies Adocia’s capacity to innovate and expand its reach. This partnership not only enhances Adocia’s research and development capabilities but also strengthens its position in the global market.

Founded in 2005, Adocia SA has consistently demonstrated a commitment to advancing the treatment of diabetes and metabolic diseases. With a robust pipeline and a strategic approach to partnerships, the company is well-positioned to make significant contributions to the biotechnology sector. As Adocia continues to navigate the challenges and opportunities of the health care industry, its focus on innovation, safety, and efficacy remains paramount. The company’s trajectory, marked by its recovery in stock price and its ambitious product pipeline, signals a promising future for patients and stakeholders alike.